 |
 |
> does anyone know anything about patch? where, when, how. nancy spires Hi Nancy, There was this tidbit in '98.... The dopamine or Sinemet patch, also known as N-0923, and well-publicized in Reader's Digest has been studied by researchers in Virginia. This treatment is not Sinemet (levodopa/carbidopa) but rather resembles Sinemet as it is a dopamine agonist. Most likely this medication will not be any better in improving symptoms than other available dopamine agonists such as pramipexole, ropinirole and pergolide. Research has been slow on this compound and there have been no national studies to show that is effective in many patients. http://www.clinical-services.med.umn.edu/movement-disorders/park3.htm I searched the Clinical Trials Search site for N-0923 http://clinicaltrials.gov/ct/gui/c/r Treatment of Parkinson's Disease with a Transdermal Skin Patch This study is currently recruiting patients. Sponsored by National Institute of Neurological Disorders and Stroke (NINDS) Purpose Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Muscle tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease. This study is designed to determine the effects of a new drug, N-9023. The drug acts like dopamine and can be given through a skin patch (transdermal) for treatment of parkinsonian symptoms. The goals of this study are to find out whether N-9023 is useful in treating the signs and symptoms of Parkinson's disease and to determine the best dose of N-9023 that is safe and effective. Condition: Parkinson Disease Treatment or Intervention: Drug: N-0923 TDS Phase: Phase II MEDLINEplus related topics: Parkinson's Disease Study Type: Clinical Trial Official Title: Transdermal Application of Dopamine Agonist N-0923 in Parkinson's Disease Further Study Details: The acute safety and antiparkinsonian efficacy of transdermally delivered N-0923 will be evaluated in patients with Parkinson's disease. This dopamine receptor agonist will be administered transdermally under double-blind conditions, in a rising dose paradigm. Antiparkinsonian activity will be quantified by means of standard rating scales. Possible adverse events will be assessed by appropriate clinical and laboratory tests. Eligibility Genders Eligible for Study: Both Criteria All patients will carry a diagnosis of Parkinson's Disease based on the presence of a characteristic clinical history and neurological findings. Symptom severity will range from Hoehn & Yahr stage II-IV. Males and females between the ages 30-76 are eligible for the study. Initial emphasis will be on patients who are taking few or no other medications than levodopa for their Parkinson's disease. No presence or history of any medical condition that can reasonably be expected to subject the patient to unwarranted risk. No patients with a history of significant cardiac (myocardial infarction within 12 months prior to study, dysrhythmia; QTc intervals greater than 440 msec). No patients who are convulsive, hepatic, or with renal disorders (exceeding the upper limit of normal values for LFT's and creatinine respectively). No patients with evidence of other serious medical illness, a history of alcohol or drug abuse, those who have participated in an investigational trial within 28 days prior to study, and pregnant or nursing women or anyone not practicing effective means of birth control. Location and Contact Information Maryland National Institute of Neurological Disorders and Stroke (NINDS), 9000 Rockville Pike Bethesda, Maryland, 20892, United States; Recruiting PRPL Warren G. Magnuson Clinical Center National Institutes of Health Bethesda, Maryland, 20892-4754, United States 1-800-411-1222 [log in to unmask] Publications that lead up to this study Marsden. 1994. Problems with long-term levodopa therapy for Parkinson's disease, Clin Neuropharmacol, Vol. 17, p. S32 Chase. 1996. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease, Adv Neurol, Vol. 69, p. 497 Bravi. 1994. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms, Ann Neurol, Vol. 36, p. 27 Study ID Numbers 99-N-0104 NLM Identifier NCT00001931 Date study started May 5, 1999 Recruitment status verified June 22, 2000 Last Updated June 22, 2000 U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 http://clinicaltrials.gov/ct/gui/c/a2r/action/GetStudy/screen/ResultScreen?order=1&xml_file_id=x mlfiles%2FCC__99-N-0104.xml%40csdb&JServSessionIdcs_current=0wi8y7zyom More Info... NIH Clinical Research Studies Protocol Number: 99-N-0104 Title: Transdermal Application of Dopamine Agonist N-0923 in Parkinson's Disease Number: 99-N-0104 Summary: Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Muscle tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease. This study is designed to determine the effects of a new drug, N-9023. The drug acts like dopamine and can be given through a skin patch (transdermal) for treatment of parkinsonian symptoms. The goals of this study are to find out whether N-9023 is useful in treating the signs and symptoms of Parkinson's disease and to determine the best dose of N-9023 that is safe and effective. Sponsoring Institute: National Institute of Neurological Disorders and Stroke (NINDS) Recruitment Detail Type: Active Accrual Of New Subjects Gender: Male & Female Referral Letter Required: Yes Population Exclusion(s): Children Eligibility Criteria: All patients will carry a diagnosis of Parkinson's Disease based on the presence of a characteristic clinical history and neurological findings. Symptom severity will range from Hoehn & Yahr stage II-IV. Males and females between the ages 30-76 are eligible for the study. Initial emphasis will be on patients who are taking few or no other medications than levodopa for their Parkinson's disease. No presence or history of any medical condition that can reasonably be expected to subject the patient to unwarranted risk. No patients with a history of significant cardiac (myocardial infarction within 12 months prior to study, dysrhythmia; QTc intervals greater than 440 msec). No patients who are convulsive, hepatic, or with renal disorders (exceeding the upper limit of normal values for LFT's and creatinine respectively). No patients with evidence of other serious medical illness, a history of alcohol or drug abuse, those who have participated in an investigational trial within 28 days prior to study, and pregnant or nursing women or anyone not practicing effective means of birth control. Special Instructions: Currently Not Provided Disease Category: Nervous System and Sense Organs Keywords: Skin Patch Continuous Stimulation Dose Finding Recruitment Keywords: None Investigational Drug(s): N-0923 TDS Investigational Device(s): None Contacts: Patient Recruitment and Public Liaison Office, CC. Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Long Distance Calls: 1-800-411-1222 Fax: (301) 480-9793 Electronic Mail:[log in to unmask] Citations: Marsden. 1994. Problems with long-term levodopa therapy for Parkinson's disease, Clin Neuropharmacol, Vol. 17, p. S32 Chase. 1996. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease, Adv Neurol, Vol. 69, p. 497 Bravi. 1994. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms, Ann Neurol, Vol. 36, p. 27 If you have: Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC. Questions about specific studies, or the database in general, please contact the Protocol Coordination Service Center, CC. Technical questions regarding the Clinical Center web site, please contact the Information Systems Department, CC. National Institutes of Health (NIH) Bethesda, Maryland 20892. Last update: 08/15/2000 http://clinicalstudies.info.nih.gov/detail/A_1999-N-0104.html Someone with time can look in the LIST archives for "transdermal patch" or "N-0923". I'm sure there is plenty to choose from....... If you don't know how to search the LIST archive just ask.... (I did about 3 years ago...) Cheeerrrrz ........... murray We try to make a difference [log in to unmask]